Visit https://www.peervoice.com/RAN860 to view the entire programme with slides. After completing “Optimising Standard of Care for Patients With Axial Spondyloarthropathies: Why Gender Matters!”, participants will be able to: Recognise the differences and similarities between radiographic and non-radiographic axSpA and the need for earlier detection; Describe the unique challenges of diagnosing and treating women with axSpA; Identify patient and disease characteristics that need to be considered when selecting an appropriate long-term biologic strategy.

Visit https://www.peervoice.com/KYP860 to view the entire programme with slides. After completing “Optimising HBV Treatment Outcomes Whilst We Hunt for a Cure”, participants will be able to: Identify the importance of reducing hepatocellular carcinoma (HCC) risk and improving secondary outcomes in patients receiving viral suppressive therapy; Recognise that antiviral suppressive therapies may differ in their impact on HCC risk and secondary outcomes; Describe the latest data for suppressive therapies and their potential impact on treatment strategies.

Visit https://www.peervoice.com/PTD860 to view the entire programme with slides. After completing “Understanding Hypercapnia in Adult Respiratory Distress Syndrome: The Quest for Optimal Patient Outcomes”, participants will be able to: Explain the impact of hypercapnia on critically ill patients within the intensive care setting; Identify patients who would be candidates for low-flow extracorporeal carbon dioxide removal (ECCO2R); Evaluate how to appropriately integrate low-flow ECCO2R techniques in clinical practice.

Visit https://www.peervoice.com/VZU860 to view the entire programme with slides. After completing “Prevention and Management of Cardiovascular Adverse Events in Multiple Myeloma: Safe and Appropriate Use of Proteasome Inhibitors”, participants will be able to: Describe the cardiovascular adverse events that have been associated with use of proteasome inhibitors for treatment of multiple myeloma; Develop strategies to prevent and manage cardiovascular adverse events in patients with multiple myeloma.

Visit https://www.peervoice.com/XQB860 to view the entire programme with slides. After completing “Evolving the Treatment Paradigm in Metastatic HER2-Positive Breast Cancer: The Ongoing Story of Emerging Treatments”, participants will be able to: Summarise unmet needs in the management of metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer; Explain the rationale for novel pathways and mechanism of actions for treating advanced metastatic HER2-positive breast cancer; Analyse data from clinical trials, evaluating the efficacy and safety of novel HER2-targeted therapies.

Visit https://www.peervoice.com/BHR860 to view the entire programme with slides. After completing “Basal Cell Carcinoma: Treatment Advances for the Progressing Patient”, participants will be able to: Outline disease and patient characteristics that may make patients with BCC ineligible for curative surgery and/or radiation; Discuss treatment options for patients with advanced BCC ineligible for surgery.

Visit https://www.peervoice.com/FKG860 to view the entire programme with slides. After completing “GnRH Antagonist vs LHRH Agonist: To Desensitize or To Inhibit, That Is the Question!”, participants will be able to: Differentiate between GnRH antagonists and LHRH agonists; Describe the recent clinical trial data assessing GnRH antagonist therapy for the treatment of prostate cancer; Discuss if GnRH antagonist therapy may lead to different clinical outcomes.

Visit https://www.peervoice.com/DYT860 to view the entire programme with slides. After completing “Seizing the Moment to Improve Outcomes in Melanoma: When and in Whom Should We Consider Adjuvant Therapy?”, participants will be able to: Describe current prognosis for patients with stage III resected melanoma and the rationale for adjuvant treatment; Illustrate the impact of adjuvant immunotherapy treatment on patient outcomes, based on the evidence, in stage III resected melanoma.

Visit https://www.peervoice.com/DHB860 to view the entire programme with slides. After completing “The First Biologic in IBD: When, Which, and Why?”, participants will be able to: Describe the clinical features and treatment goals of inflammatory bowel disease (IBD); Identify patient and drug characteristics that may influence treatment decision-making for patients with IBD; Formulate individualised treatment plans for patients with IBD who require biologic treatment, considering patient-specific factors.

Visit https://www.peervoice.com/MXF860 to view the entire programme with slides. After completing “Practical Strategies in Optimising Subcutaneous Immunoglobulin Replacement Therapy”, participants will be able to: Recognise the differences between the clinical profiles of each Ig replacement modality; Describe the appropriate Ig modality based on patient preference and clinical criteria; Anticipate adverse reactions and side effects associated with subcutaneous Ig use and develop appropriate strategies to manage or avoid them.